Pneumocystis pneumonia (PCP) is treated with a 21-day course of a strong antibiotic combination called TMP-SMX, which remains the most effective option for both mild and severe cases. PCP is a serious lung infection caused by the fungus Pneumocystis jirovecii, and it primarily affects people with weakened immune systems, particularly those living with HIV or taking immunosuppressive medications after organ transplants or for autoimmune conditions.
First-Line Treatment for PCP
TMP-SMX (trimethoprim-sulfamethoxazole) is the gold standard treatment regardless of how severe the infection is. The standard course lasts 21 days. For mild to moderate cases, it can be taken as pills. For severe cases where oxygen levels are dangerously low, it’s given intravenously in the hospital until the patient stabilizes enough to switch to oral pills.
The catch is that the doses needed to treat PCP are significantly higher than those used for common infections like urinary tract infections. These high therapeutic doses are effective but come with a substantial rate of side effects, including skin rashes, nausea, drops in blood cell counts, kidney problems, liver inflammation, and elevated potassium levels. Side effects are common enough that many patients end up needing to switch to a second-line medication partway through treatment.
Mild vs. Severe PCP: Why It Matters
The severity of PCP determines not just how the medication is delivered but whether steroids are added to the treatment plan. Severity is assessed by measuring oxygen levels in the blood. Patients with moderate to severe disease, identified by low oxygen readings, receive corticosteroids alongside their antibiotic treatment. Steroids reduce the intense lung inflammation that occurs as the immune system fights the infection, and in severe cases, this inflammation itself can be life-threatening.
Steroids are typically started at the same time as antibiotic therapy or within 72 hours. They’re tapered over about three weeks. For mild cases where oxygen levels are adequate, steroids aren’t necessary and antibiotic treatment alone is sufficient.
Options When TMP-SMX Isn’t Tolerated
Because side effects from high-dose TMP-SMX are so frequent, second-line options are well established. The choice depends on disease severity.
For mild to moderate PCP, the main alternatives are:
- Atovaquone: Taken by mouth twice daily with food. It’s less effective than TMP-SMX but causes fewer side effects, making it a practical option for people who can’t tolerate the first-line drug. The most common issues are headache, nausea, diarrhea, and rash.
- Primaquine plus clindamycin: Both taken by mouth. This combination is effective but carries risks of anemia and, in people with a genetic condition called G6PD deficiency, can cause dangerous destruction of red blood cells. Screening for G6PD deficiency is important before starting primaquine.
For moderate to severe PCP, the alternatives narrow:
- Primaquine plus clindamycin (given intravenously): Many clinicians actually prefer this combination over the other severe-case alternative because it tends to be more effective and less toxic.
- IV pentamidine: Reserved for severe cases that have failed other treatments. Pentamidine carries serious risks including dangerous drops in blood sugar from damage to pancreatic cells, kidney toxicity, dangerously low blood pressure, and electrolyte imbalances. Because of these toxicities, it’s generally a last resort.
If the initial treatment fails entirely, research suggests that the combination of primaquine and clindamycin may be the most effective salvage therapy based on meta-analyses and cohort studies.
PCP in People Without HIV
PCP doesn’t only affect people with HIV. It also occurs in people on immunosuppressive medications for organ transplants, cancer chemotherapy, or autoimmune diseases. The infection behaves quite differently in these two groups, and the differences are clinically significant.
In people without HIV, PCP tends to come on fast and hit harder. Symptoms develop over a median of about 5 days, compared to around 21 days in people with HIV. Oxygen levels drop more severely, requiring higher supplemental oxygen. Non-HIV patients are more likely to need intensive care and mechanical ventilation. The hospital mortality rate reflects this stark difference: 27% for non-HIV patients compared to 4% for those with HIV, according to a large French study. Older age, bone marrow transplant history, need for mechanical ventilation, and delays in starting treatment all increase the risk of death.
The core treatment is the same, TMP-SMX for 21 days, but the role of corticosteroids in non-HIV patients is less clearly established than in HIV-positive patients. Despite the higher mortality, the treatment framework doesn’t fundamentally change; the urgency of early diagnosis and rapid treatment initiation is simply amplified.
What to Expect During Treatment
PCP treatment typically takes the full 21 days regardless of which medication is used. Improvement doesn’t happen overnight. It’s normal for symptoms to take several days to begin improving, and in some cases patients may initially feel worse before they feel better, particularly as inflammation flares. A lack of improvement after four to eight days of appropriate therapy generally raises concern about treatment failure, at which point a switch to salvage therapy may be considered.
During treatment, regular blood work is standard. High-dose TMP-SMX can suppress bone marrow function, raise potassium levels, and stress the kidneys and liver. In one study of kidney transplant recipients on TMP-SMX, roughly one in five developed elevated potassium levels requiring dose adjustments, and nearly one in four developed low white blood cell counts. These side effects are manageable when caught early through monitoring, which is why blood tests are drawn frequently throughout the course.
Preventing PCP Before and After Treatment
For people living with HIV, PCP prevention revolves around immune system strength, measured by CD4 cell count. Preventive medication (prophylaxis) is recommended when CD4 counts fall below 200 cells per cubic millimeter, with the threshold depending partly on whether HIV viral load is detectable. The same drug used for treatment, TMP-SMX, is used for prevention, just at a much lower dose.
Once antiretroviral therapy (ART) strengthens the immune system and CD4 counts rise above 200 and stay there for at least three months, preventive medication can generally be stopped. If CD4 counts drop again, prophylaxis restarts.
After a confirmed episode of PCP, secondary prophylaxis begins immediately once the 21-day treatment course finishes. This continues until ART has restored CD4 counts above 200 for at least three months. For people who developed PCP despite having a CD4 count above 200 while already on ART, lifelong prophylaxis is generally recommended as a precaution, since the infection occurred despite what should have been adequate immune function.
For non-HIV immunocompromised patients, the decision to use prophylaxis depends on the specific immunosuppressive regimen and the degree of immune suppression involved. The principles are similar: prevent the infection before it starts, because PCP carries substantial mortality even with prompt treatment.